Strata Skin Scien (SSKN)

$0.17 -0.02 (-9.91%)
Market Cap 1.12M
Revenue (ttm) 33.56M
Net Income (ttm) -10.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -30.07%
Debt to Equity Ratio 11.69
Volume 616,100
Avg Vol 533,192
Day's Range N/A - N/A
Shares Out 5.89M
Stochastic %K 1%
Beta 0.33
Analysts Strong Sell
Price Target $7.40

Company Profile

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, and other...

Industry: Medical Devices
Sector: Healthcare
Phone: 215 619 3200
Fax: 215 619 3209
Address:
5 Walnut Grove Drive, Suite 140, Horsham, United States
ValueVester
ValueVester Feb. 28 at 1:28 PM
$SSKN Friday’s SEC filings are routine when a publicly traded company delist. SSKN is in hot water but Accelmed’s interests align with common share holders. Accelmed owns 20% of SSKN. Because: • Accelmed is an insider • Management has inside information • They sit on the board Any take-private would be reviewed under “entire fairness act”, not business judgment. That means they must show: • Fair dealing (process) • Fair price (economics) A “grab it for pennies” deal is exactly what gets PE sued and often overturned. Fair EV is about $8-$9. Anything lower they would have shareholder suits. I would unfortunately be one of those shareholders going after them, but Accelmed is not known for sketchy takeovers.
0 · Reply
lecorb
lecorb Feb. 27 at 12:52 PM
$SSKN Run long and short before losing all your investments. Suggestion! STRATA Skin Sciences (SSKN) filed a Form 25 with the SEC to deregister its common stock. Trading of the Company’s common stock was suspended on Nasdaq at the opening of business on February 19, 2026. SSKN expects to file a Form 15 on or about March 2, 2026, to terminate registration. The Form 15 filing will also suspend STRATA’s reporting obligations, effectively initiating a “going dark” process.
1 · Reply
ValueVester
ValueVester Feb. 26 at 12:20 AM
$SSKN that’s crazy. Sorry. Not saying buyers here are going to make a lot of money, but just not being able to have the opportunity to buy a distressed asset with good management and known catalysts is frustrating. I would like to see Robinhood free this up. I would make a phone call and ask them why?
2 · Reply
MiraMax
MiraMax Feb. 25 at 7:49 PM
$SSKN get a real brokerage account with schwab or fidelity.
0 · Reply
STOCKYSTOCK
STOCKYSTOCK Feb. 25 at 2:54 AM
$SSKN
0 · Reply
ValueVester
ValueVester Feb. 24 at 11:22 PM
$SSKN @STOCKYSTOCK were you able to buy on Robinhood today?
1 · Reply
ValueVester
ValueVester Feb. 24 at 1:28 AM
$SSKN ohhh boy. That must be frustrating at these levels.
0 · Reply
STOCKYSTOCK
STOCKYSTOCK Feb. 23 at 10:32 PM
$SSKN yeah, and i cannot buy! i only have 25k shares
0 · Reply
ValueVester
ValueVester Feb. 23 at 10:13 PM
$SSKN not going to have any excitement here yet, but this will be back at $1.00 by the end of the week. That’s not saying much, because I still think this should be at a fair value of like $6.00 - $7.00. After CPT code expansion $9.00 - $12.00, buyout $15.00 - $20.00. This is of course assuming revenues increase in stride with these predictions. Nasdaq market makers treated SSKN like poop. Granted it kinda is, but u gotta believe in Uri and Dolev’s track record. I believe they are fighters.
0 · Reply
jeco
jeco Feb. 23 at 6:55 PM
$SSKN So who's buying as it seems retailers (Robinhood and Webull that I know of) cannot? 🤷
0 · Reply
Latest News on SSKN
No data available.
ValueVester
ValueVester Feb. 28 at 1:28 PM
$SSKN Friday’s SEC filings are routine when a publicly traded company delist. SSKN is in hot water but Accelmed’s interests align with common share holders. Accelmed owns 20% of SSKN. Because: • Accelmed is an insider • Management has inside information • They sit on the board Any take-private would be reviewed under “entire fairness act”, not business judgment. That means they must show: • Fair dealing (process) • Fair price (economics) A “grab it for pennies” deal is exactly what gets PE sued and often overturned. Fair EV is about $8-$9. Anything lower they would have shareholder suits. I would unfortunately be one of those shareholders going after them, but Accelmed is not known for sketchy takeovers.
0 · Reply
lecorb
lecorb Feb. 27 at 12:52 PM
$SSKN Run long and short before losing all your investments. Suggestion! STRATA Skin Sciences (SSKN) filed a Form 25 with the SEC to deregister its common stock. Trading of the Company’s common stock was suspended on Nasdaq at the opening of business on February 19, 2026. SSKN expects to file a Form 15 on or about March 2, 2026, to terminate registration. The Form 15 filing will also suspend STRATA’s reporting obligations, effectively initiating a “going dark” process.
1 · Reply
ValueVester
ValueVester Feb. 26 at 12:20 AM
$SSKN that’s crazy. Sorry. Not saying buyers here are going to make a lot of money, but just not being able to have the opportunity to buy a distressed asset with good management and known catalysts is frustrating. I would like to see Robinhood free this up. I would make a phone call and ask them why?
2 · Reply
MiraMax
MiraMax Feb. 25 at 7:49 PM
$SSKN get a real brokerage account with schwab or fidelity.
0 · Reply
STOCKYSTOCK
STOCKYSTOCK Feb. 25 at 2:54 AM
$SSKN
0 · Reply
ValueVester
ValueVester Feb. 24 at 11:22 PM
$SSKN @STOCKYSTOCK were you able to buy on Robinhood today?
1 · Reply
ValueVester
ValueVester Feb. 24 at 1:28 AM
$SSKN ohhh boy. That must be frustrating at these levels.
0 · Reply
STOCKYSTOCK
STOCKYSTOCK Feb. 23 at 10:32 PM
$SSKN yeah, and i cannot buy! i only have 25k shares
0 · Reply
ValueVester
ValueVester Feb. 23 at 10:13 PM
$SSKN not going to have any excitement here yet, but this will be back at $1.00 by the end of the week. That’s not saying much, because I still think this should be at a fair value of like $6.00 - $7.00. After CPT code expansion $9.00 - $12.00, buyout $15.00 - $20.00. This is of course assuming revenues increase in stride with these predictions. Nasdaq market makers treated SSKN like poop. Granted it kinda is, but u gotta believe in Uri and Dolev’s track record. I believe they are fighters.
0 · Reply
jeco
jeco Feb. 23 at 6:55 PM
$SSKN So who's buying as it seems retailers (Robinhood and Webull that I know of) cannot? 🤷
0 · Reply
STOCKYSTOCK
STOCKYSTOCK Feb. 23 at 5:47 PM
$SSKN when the heck will Robinhood let me buy! This is going to leave the dang station before i can buy the quantity i want!!!!!
1 · Reply
ValueVester
ValueVester Feb. 23 at 2:45 AM
$SSKN For Accelmed, I recall that they have a $400 million med tech fund. If they acquired Strata for $9.50/share (their average price per share) or $57 million, it would align well with what PE firms actually do. Take it private, wait for CPT code expansion, then sell company for $90 million. Just one of my evening rants, but in a competent review of the company by an independent advisor, it would value the company around $8 - $12 per share, to avoid long drawn out shareholder suits.
0 · Reply
ValueVester
ValueVester Feb. 23 at 2:33 AM
$SSKN For Strata pricing below ~$7 would: • Look punitive to minorities • Look irrational to LPs • Invite lawsuits That floors a deal higher than retail assumes. Enterprise math (not stock price) Using ~6.0M shares: • $8/share ≈ $48M equity • $9/share ≈ $54M equity That implies an enterprise value that is: • Modest relative to historical revenue • Cheap relative to CPT option value In similar PE-led med-tech take-privates: • Prices cluster around “defensible fairness” • Not fire-sale lows • Not blue-sky highs That range is usually: “Enough to clear legal hurdles, not enough to overpay.” For SSKN, that math naturally lands in $8–$9. Because Accelmed: • Is a large insider • Has board representation • Has inside information They cannot take the company private at a “distressed OTC print” without: • A fairness opinion • Litigation risk (appraisal rights, entire-fairness review) Historically, that pushes pricing to: • ~0.9–1.2× a conservative equity value.
0 · Reply
ValueVester
ValueVester Feb. 22 at 2:40 AM
$SSKN I think Accelmed could propose a take private deal, but it would have to be somewhere around $8? Like 1x expected sales after CPT approval.
0 · Reply
ValueVester
ValueVester Feb. 22 at 2:34 AM
$SSKN I just don’t know if they can legally do this without getting themselves in trouble.
0 · Reply
ValueVester
ValueVester Feb. 22 at 2:33 AM
$SSKN …or would this open the board and Accelmed to legal exposure because they are not preserving cash? Not sure. I’m a long term shareholder who has averaged down. I am sticking in here hoping that they can turn the valuation around and reward shareholders. That is their job. Just some crazy Saturday night thoughts. Companies do announce buybacks when price per share drops like this.
0 · Reply
ValueVester
ValueVester Feb. 22 at 2:19 AM
$SSKN Message to Management. New thought process unlocked. Use $180,000 of the cash on hand to buy back and retire 1,000,000 shares. Go from 6mil shares outstanding to 5mil shares outstanding. This decreases float and increases valuation for very cheap. I love this idea. Clearly it increases shareholder value. Get really crazy and buy back 2mil shares for $360,000 and a lot changes on the valuation side. This type of decision would immediately increase the value of Accelmed’s position. I think they can do this?
0 · Reply
STOCKYSTOCK
STOCKYSTOCK Feb. 21 at 8:53 PM
$SSKN seems like very few can buy through their Brokers……. all can sell concerned when we can buy this thing shoots up to fast. Was hoping to buy under .20 but that seems to be fading
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 6:30 PM
$SSKN Current Stock Price: $0.19
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 3:26 PM
$SSKN RSI: 18.52, MACD: -0.2785 Vol: 0.44, MA20: 0.92, MA50: 1.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuzanneGee1021
SuzanneGee1021 Feb. 21 at 7:57 AM
$SSKN Strata Skin Sciences develops dermatology platforms. Revenue growth depends on adoption. Balance sheet risk remains.
1 · Reply
STOCKYSTOCK
STOCKYSTOCK Feb. 20 at 3:51 PM
$SSKN still cannot buy on Robinhood….. if it stays near this level i will buy another 100k no reason not to imo no history of 2 decades company diluting and they are marching forward with business…. seem honest
0 · Reply